Multilevel models for meta-analysis, and their application to absolute risk differences

被引:76
作者
Thompson, SG
Turner, RM
Warn, DE
机构
[1] Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England
[2] MRC, Clin Trials Unit, London, England
关键词
D O I
10.1191/096228001682157616
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Meta-analysis can be considered a multilevel statistical problem, since information within studies is combined in the presence of potential heterogeneity between studies. Here a general multilevel model framework is developed for meta-analysis to combine either summary data or individual patient outcome data from each study, and to include either study or individual level covariates that might explain heterogeneity. Classical and Bayesian approaches to estimation are contrasted. These methods are applied to a meta-analysis of trials of thrombolytic therapy after myocardial infarction. Subgroups within the trials were available, categorized by the time delay until treatment, so that a three-level random effects model that includes time delay as a covariate is proposed. In addition it was desired to represent the treatment effect as an absolute risk reduction, rather than the conventional odds ratio. We show how this can be achieved within a Bayesian analysis, while still recognizing the binary nature of the original outcome data.
引用
收藏
页码:375 / 392
页数:18
相关论文
共 52 条
[1]  
ABRAMS KR, 2000, METAANALYSIS MED HLT, P29
[2]  
[Anonymous], 1998, HLTH TECHNOLOGY ASSE
[3]   INDICATIONS FOR FIBRINOLYTIC THERAPY IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - COLLABORATIVE OVERVIEW OF EARLY MORTALITY AND MAJOR MORBIDITY RESULTS FROM ALL RANDOMIZED TRIALS OF MORE THAN 1000 PATIENTS [J].
APPLEBY, P ;
BAIGENT, C ;
COLLINS, R ;
FLATHER, M ;
PARISH, S ;
PETO, R ;
BELL, P ;
HALLS, H ;
MEAD, G ;
DIAZ, R ;
PAOLASSO, E ;
PAVIOTTI, C ;
ROMERO, G ;
CAMPBELL, T ;
OROURKE, MF ;
THOMPSON, P ;
LESAFFRE, E ;
VANDEWERF, F ;
VERSTRAETE, M ;
ARMSTRONG, PW ;
CAIRNS, JA ;
MORAN, C ;
TURPIE, AG ;
YUSUF, S ;
GRANDE, P ;
HEIKKILA, J ;
KALA, R ;
BASSAND, JP ;
BOISSEL, JP ;
BROCHIER, M ;
LEIZOROVICZ, A ;
BRUGGEMANN, T ;
KARSCH, KR ;
KASPER, W ;
LAMMERTS, D ;
NEUHAUS, KL ;
MEYER, J ;
SCHRODER, R ;
VONESSEN, R ;
SARAN, RK ;
ARDISSINO, D ;
BONADUCE, D ;
BRUNELLI, C ;
CERNIGLIARO, C ;
FORESTI, A ;
FRANZOSI, MG ;
GUIDUCCI, D ;
MAGGIONI, A ;
MAGNANI, B ;
MATTIOLI, G .
LANCET, 1994, 343 (8893) :311-322
[4]   Subgroup analysis and other (mis)uses of baseline data in clinical trials [J].
Assmann, SF ;
Pocock, SJ ;
Enos, LE ;
Kasten, LE .
LANCET, 2000, 355 (9209) :1064-1069
[5]  
Berkey CS, 1998, STAT MED, V17, P2537, DOI 10.1002/(SICI)1097-0258(19981130)17:22<2537::AID-SIM953>3.0.CO
[6]  
2-C
[7]   A RANDOM-EFFECTS REGRESSION-MODEL FOR METAANALYSIS [J].
BERKEY, CS ;
HOAGLIN, DC ;
MOSTELLER, F ;
COLDITZ, GA .
STATISTICS IN MEDICINE, 1995, 14 (04) :395-411
[8]   Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour [J].
Boersma, E ;
Maas, ACP ;
Deckers, JW ;
Simoons, ML .
LANCET, 1996, 348 (9030) :771-775
[9]  
Briggs A, 1998, J Health Serv Res Policy, V3, P233
[10]   METAANALYSIS FOR 2X2 TABLES - A BAYESIAN-APPROACH [J].
CARLIN, JB .
STATISTICS IN MEDICINE, 1992, 11 (02) :141-158